Loading
Life sciences · Journal article
Journal of Nanobiotechnology · November 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Colorectal cancer peritoneal metastasis (PM) is characterized by rapid progression, pathological angiogenesis, malignant ascites, and an M2 macrophage-dominated tumor microenvironment, which limit the efficacy of single-agent therapy. Herein, we constructed Reg@BFP-HM NPs by associating a hyaluronic acid-mitomycin C (HA-MMC, HM) with regorafenib-loaded folic acid/phenylboronic acid-modified bovine serum albumin nanoparticles (Reg@BFP NPs). Reg@BFP and HM were assembled into an integrated nanostructure through multiple interactions. As a targeted therapeutic nanoplatform, BFP-HM enables folate receptor/CD44-mediated tumor delivery and improves the dispersion of Reg and MMC. After intraperitoneal administration, Reg@BFP-HM NPs showed stronger antitumor efficacy than either component alone. HM exerts potent cytotoxicity to eliminate tumor cells, whereas Reg inhibits angiogenesis and tumor proliferation through suppression of the VEGFR2/ERK pathway. In addition, BFP activates the TLR4/NF-κB pathway to promote macrophage reprogramming toward a pro-inflammatory phenotype, which acts in synergy with Reg to suppress the formation of malignant ascites. In a CT26-luc PM mouse model, Reg@BFP-HM NPs inhibited peritoneal tumor growth, markedly reduced ascites volume, and prolonged survival without obvious systemic toxicity. These results highlight the potential of Reg@BFP-HM NPs as a chemo-antiangiogenic strategy for PM treatment.